Regulatory Toxicology

Charles O'Neill

Dr. O'Neill serves as a member of the Executive Board and provides consulting on many aspects of vision science with a specific focus on drug development and nonclinical considerations for regulatory submissions.  Dr. O’Neill has 30 years of biotechnology and pharmaceutical development experience.  Currently, he is a Co-Founder, Chief Executive Officer and Board Chair at MCAL Therapeutics, Inc. that is developing a novel evaporative dry eye therapy. From 2004 to 2023 Dr.